INS and type 1 diabetes mellitus: In a study led by Nassar et al. at the Sahel Teaching Hospital and Cairo University (NCT02138331), UCB-MSC-Exos are tested in T1DM patients aged between 18 and 60 years with reduction of C-peptide chain more than 50%, C-peptide of more than 0.8 ng/mL at Screening, and requiring insulin ≥ 0.4 IU per kg per day.